Literature DB >> 21331354

Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers.

Youyun Yang1, Hailan Liu, Zhaomin Li, Zijin Zhao, Michelle Yip-Schneider, Qipeng Fan, C Max Schmidt, E Gabriela Chiorean, Jingwu Xie, Liang Cheng, Jey-Hsin Chen, Jian-Ting Zhang.   

Abstract

Human fatty acid synthase (FASN) is a homo-dimeric protein with multi-enzymatic activity responsible for the synthesis of palmitate. FASN expression has been found to be up-regulated in multiple types of human cancers and its expression correlates with poor prognosis possibly by causing treatment resistance. In this study, we tested if FASN expression is up-regulated in human pancreatic cancers and if its higher expression level in pancreatic cancers causes intrinsic resistance to gemcitabine and radiation. We found that FASN expression is significantly up-regulated in human pancreatic cancer tissues without any correlation to age, sex, race, and tumor stage. Knocking down or over-expressing FASN significantly down- or up-regulate resistance of pancreatic cancer cell lines to both gemcitabine and radiation treatments. These findings imply that the elevated FASN expression in pancreatic cancers may contribute to unsuccessful treatments of pancreatic cancers by causing intrinsic resistance to both chemotherapy and radiation therapy.

Entities:  

Keywords:  Human fatty acid synthase (FASN); gemcitabine; palmitate; pancreatic cancers; radiation treatments; treatment resistance

Year:  2011        PMID: 21331354      PMCID: PMC3039422     

Source DB:  PubMed          Journal:  Int J Biochem Mol Biol        ISSN: 2152-4114


  26 in total

1.  Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome.

Authors:  Agnieszka K Witkiewicz; Katherine H Nguyen; Abhijit Dasgupta; Eugene P Kennedy; Charles J Yeo; Michael P Lisanti; Jonathan R Brody
Journal:  Cell Cycle       Date:  2008-10-23       Impact factor: 4.534

2.  Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker.

Authors:  Hailan Liu; Jing-Yuan Liu; Xi Wu; Jian-Ting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2010-07-18

3.  Regulation of function by dimerization through the amino-terminal membrane-spanning domain of human ABCC1/MRP1.

Authors:  Youyun Yang; Yang Liu; Zizheng Dong; Junkang Xu; Hui Peng; Zhaoqian Liu; Jian-Ting Zhang
Journal:  J Biol Chem       Date:  2007-01-30       Impact factor: 5.157

4.  The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung.

Authors:  C J Piyathilake; A R Frost; U Manne; W C Bell; H Weiss; D C Heimburger; W E Grizzle
Journal:  Hum Pathol       Date:  2000-09       Impact factor: 3.466

5.  Cohort study of fatty acid synthase expression and patient survival in colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Jeffrey A Meyerhardt; Gregory J Kirkner; Andrew T Chan; Takako Kawasaki; Edward L Giovannucci; Massimo Loda; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

6.  Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma. A clinicopathological study.

Authors:  Sabrina D Silva; Michelle Agostini; Inês N Nishimoto; Ricardo D Coletta; Fábio A Alves; Márcio A Lopes; Luiz P Kowalski; Edgard Graner
Journal:  Oral Oncol       Date:  2004-08       Impact factor: 5.337

7.  Differential expression of fatty acid synthase (FAS) and ErbB2 in nonmalignant and malignant oral keratinocytes.

Authors:  Sabrina D Silva; Isabela W Cunha; Ana Lúcia C A Rangel; Jacks Jorge; Karina G Zecchin; Michelle Agostini; Luiz P Kowalski; Ricardo D Coletta; Edgard Graner
Journal:  Virchows Arch       Date:  2008-06-06       Impact factor: 4.064

8.  Expression of the lipogenic enzyme fatty acid synthase (FAS) as a predictor of poor outcome in nephroblastoma: an interinstitutional study.

Authors:  Francesca Diomedi Camassei; Alessandro Jenkner; Lucilla Ravà; Cesare Bosman; Paola Francalanci; Alberto Donfrancesco; Piero L Alò; Renata Boldrini
Journal:  Med Pediatr Oncol       Date:  2003-05

9.  Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells.

Authors:  Akio Horiguchi; Tomohiko Asano; Takako Asano; Keiichi Ito; Makoto Sumitomo; Masamichi Hayakawa
Journal:  J Urol       Date:  2008-06-13       Impact factor: 7.450

10.  Serum fatty acid synthase as a marker of pancreatic neoplasia.

Authors:  Kim Walter; Seung-Mo Hong; Sinead Nyhan; Marcia Canto; Neal Fedarko; Alison Klein; Margaret Griffith; Noriyuki Omura; Susan Medghalchi; Frank Kuhajda; Michael Goggins
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-01       Impact factor: 4.254

View more
  47 in total

1.  Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.

Authors:  Joshua J Souchek; Amanda L Davis; Tanner K Hill; Megan B Holmes; Bowen Qi; Pankaj K Singh; Steven J Kridel; Aaron M Mohs
Journal:  Mol Cancer Ther       Date:  2017-06-14       Impact factor: 6.261

Review 2.  Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer.

Authors:  Julian Swierczynski; Areta Hebanowska; Tomasz Sledzinski
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

3.  FASN regulates cellular response to genotoxic treatments by increasing PARP-1 expression and DNA repair activity via NF-κB and SP1.

Authors:  Xi Wu; Zizheng Dong; Chao J Wang; Lincoln James Barlow; Valerie Fako; Moises A Serrano; Yue Zou; Jing-Yuan Liu; Jian-Ting Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-24       Impact factor: 11.205

Review 4.  Biological determinants of radioresistance and their remediation in pancreatic cancer.

Authors:  Parthasarathy Seshacharyulu; Michael J Baine; Joshua J Souchek; Melanie Menning; Sukhwinder Kaur; Ying Yan; Michel M Ouellette; Maneesh Jain; Chi Lin; Surinder K Batra
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-02-27       Impact factor: 10.680

5.  Immunohistochemical expressions of fatty acid synthase and phosphorylated c-Met in thyroid carcinomas of follicular origin.

Authors:  Jing Liu; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2011-10-30

Review 6.  Targeting metabolic vulnerabilities of cancer: Small molecule inhibitors in clinic.

Authors:  Satyendra C Tripathi; Johannes F Fahrmann; Jody V Vykoukal; Jennifer B Dennison; Samir M Hanash
Journal:  Cancer Rep (Hoboken)       Date:  2018-09-23

7.  Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo.

Authors:  W Huang; Z Dong; Y Chen; F Wang; C J Wang; H Peng; Y He; G Hangoc; K Pollok; G Sandusky; X-Y Fu; H E Broxmeyer; Z-Y Zhang; J-Y Liu; J-T Zhang
Journal:  Oncogene       Date:  2015-06-15       Impact factor: 9.867

8.  Inhibition of FASN expression enhances radiosensitivity in human non-small cell lung cancer.

Authors:  Ning Zhan; Bin Li; Xiangying Xu; Jianyu Xu; Songliu Hu
Journal:  Oncol Lett       Date:  2018-01-29       Impact factor: 2.967

9.  Fatty acid synthase causes drug resistance by inhibiting TNF-α and ceramide production.

Authors:  Hailan Liu; Xi Wu; Zizheng Dong; Zhiyong Luo; Zhenwen Zhao; Yan Xu; Jian-Ting Zhang
Journal:  J Lipid Res       Date:  2013-01-14       Impact factor: 5.922

10.  Fatty acid synthase overexpression confers an independent prognosticator and associates with radiation resistance in nasopharyngeal carcinoma.

Authors:  Yu-Chien Kao; Sung-Wei Lee; Li-Ching Lin; Li-Tzong Chen; Chung-Hsi Hsing; Han-Ping Hsu; Hsuan-Ying Huang; Yow-Ling Shiue; Tzu-Ju Chen; Chien-Feng Li
Journal:  Tumour Biol       Date:  2012-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.